Iambic Therapeutics director Evan Lockwood Rachlin reports $11.5 million common share acquisition
IAM•Iambic Therapeutics director Evan Lockwood Rachlin reported an indirect purchase of 718,750 common shares at $16 each, worth $11.5 million. Preferred stock and convertible promissory note conversions added 1,927,252 shares, bringing his reported indirect holdings to 2,646,002 shares.
1. Reported share acquisition
Iambic Therapeutics director Evan Lockwood Rachlin reported an indirect purchase of 718,750 common shares at $16 per share. Conversions of preferred stock and convertible promissory notes added 1,927,252 common shares, bringing his reported indirect holdings to 2,646,002 shares.
